|
Evaluations of Biomarkers CDX1 and CDX2 in Gastric Cancer Prognosis: A Meta-analysis
|
Azadeh Khayyat    1, Mohammad Ali Esmaeil Pour2 , Olia Poursina3 , Seyed Amir Zohouti4 , Pragya Virendrakumar Jian5 , Neel Patel6 , Ali Amin3 |
1- Department of Pathology, Medical College of Wisconsin, WI, USA. , azadeh.khayyat.ak@gmail.com
2- Department of Rheumatology, Medical College of Georgia at Augusta University, GA, USA.
3- Department of Pathology, Brown University, RI, USA.
4- College student, Simon Fraser University, Department of Science, BC, Canada.
5- Department of Pathology, Medical College of Wisconsin, WI, USA.
6- Department of Public Health, Icahn School of Medicine at Mount Sinai, NY, USA. |
|
|
Abstract: (145 Views) |
| CDX1 and CDX2 are homeobox-type transcription factors that are potential biomarkers and are associated with prognostic significance in intestinal-type gastric cancer early disease before lymph node metastasis is associated with better prognosis. In addition, the genes IDH 1 and IDH 2 previously known to be involved in brain cancer are implicated in cancer-related molecular signatures as a result new targeted personalized therapies may be possible. Our retrospective study determined the correlation between CDX markers and clinicopathologic data including survival in patients with gastric cancer. This study included studies from 1997 to December 2022 a meta-analysis to provide odds ratios (ORs) and relative risks (RRs). We discussed in detail the impact of IDH 1/2 on the prognosis of gastric cancer outcomes and potential therapeutic strategies. Our meta-analysis included 20 studies identifying 11,163 patients with gastric cancer. We found that CDX 1 overexpression was associated with better overall survival (pooled HR: 1.28) and CDX 2 expression and better 3-year survival (pooled HR: 1.64) and 5-year survival was the pooled HR was correlated 1 94 with both showing statistical correlation. Evidence suggests that IDH 1/2 mutations and CDX 1/2 overexpression are closely associated with metabolic abnormalities epigenetic changes and mutations evidence suggests the potential for novel targeted therapies in gastric cancer. CDX 1/2 overexpression is associated with a favorable prognosis in gastric cancer cases. Further studies are needed to explore the clinical significance of IDH 1/2 mutations and CDX 1/2 expression. |
|
| Keywords: Gastric cancer, CDX2, CDX1, IDH1, IDH2 prognosis, biomarker, stomach cancer |
|
|
Full-Text [PDF 1310 kb]
(24 Downloads)
|
Type of Study: Review |
Subject:
Biomarkers (diagnosis & treatment)
Received: 2024/01/16 | Accepted: 2024/05/29 | Published: 2024/07/10
|
|
|
|
|
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
